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Background: Few studies have assessed the time to blood culture positivity as a predictor of clinical outcome in
fungal bloodstream infections (BSIs). The purpose of this study was to evaluate the time to positivity (TTP) of blood
cultures in patients with Candida albicans BSIs and to assess its impact on clinical outcome.
Methods: A historical cohort study with 89 adults patients with C. albicans BSIs. TTP was defined as the time
between the start of incubation and the time that the automated alert signal indicating growth in the culture
bottle sounded.
Results: Patients with BSIs and TTPs of culture of ≤36 h (n=39) and >36 h (n=50) were compared. Septic shock
occurred in 46.2% of patients with TTPs of ≤36 h and in 40.0% of patients with TTP of >36 h (p=0.56). A central
venous catheter source was more common with a BSI TTP of ≤36 h (p=0.04). Univariate analyis revealed that
APACHE II score≥20 at BSI onset, the development of at least one organ system failure (respiratory, cardiovascular,
renal, hematologic, or hepatic), SOFA at BSI onset, SAPS II at BSI onset, and time to positivity were associated with
death. By using logistic regression analysis, the only independent predictor of death was time to positivity (1.04;
95% CI, 1.0-1.1, p=0.035), with the chance of the patient with C. albicans BSI dying increasing 4.0% every hour prior
to culture positivity.
Conclusion: A longer time to positivity was associated with a higher mortality for Candida albicans BSIs; therefore,
initiating empiric treatment with antifungals may improve outcomes.
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Candidemia is a serious problem in tertiary hospitals all
over the world [1-3]. Despite a relatively low incidence,
it is associated with higher rates of morbidity and mor-
tality [1-3].
The use of automated systems for blood cultures was
one of the great advances in the diagnosis of candidemia
[4,5]. This method offers improved sensitivity, which is es-
timated to be approximately 70% [5]. Currently, it appears* Correspondence: alexandre.marra@einstein.br
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reproduction in any medium, provided the orthat the number of these infections has stabilized, al-
though their mortality remains unchanged [1-3,5].
Candida albicans is still the primary cause of these in-
fections, representing on average half of the cases [1,6].
The increase in non-albicans species, carries therapeutic
implications because the pattern of susceptibility to azoles
is species-specific [3,6].
As with all infectious processes, rapid diagnosis of fun-
gal infection combined with appropriate treatment re-
duces early mortality [5-7]. Blood cultures, still considered
the gold standard in the diagnosis of these infections, can
take days to turn positive and even longer to identify the
species [5,6,8].
Time to blood culture positivity (TTP) has recently been
used diagnostically and prognostically for bacteremiaLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Nunes et al. BMC Infectious Diseases 2013, 13:486 Page 2 of 7
http://www.biomedcentral.com/1471-2334/13/486[9-11]. Given the paucity of data on TTP in BSI by Can-
dida species, the present study aims at better understand-
ing it and its impact on clinical outcome.
Methods
Setting
Hospital São Paulo, at the Universidade Federal de São
Paulo is a 700-bed tertiary-care facility in São Paulo,
Brazil. The hospital houses four intensive care units
(ICUs), including a pediatric ICU. This study was ap-
proved by the Ethics Committee of the Universidade
Federal de São Paulo.
Study design
Patients with BSIs from 1 January 2002 through 31 July
2009 were identified retrospectively by use of the elec-
tronic medical microbiology record. For each case, the
time to blood culture positivity was retrieved from the
hospital's automated blood culture instrument. The med-
ical microbiology record identified the patient by medical
record number so that a retrospective chart review could
be conducted. Patients were considered to have had a BSI
due to Candida spp if one or more blood cultures were
positive for this organism. Each patient was included only
once, at the time of the first BSI. Patients less than 18
years old, those with polymicrobial infections, and those
receiving antifungal therapy at the time of the BSI were
excluded from the analysis.
Data collected included age; gender; location of the pa-
tient (ward versus ICU); the duration of hospitalization
prior to the onset of the BSI; the presence of predispos-
ing clinical factors, including neutropenia (defined as an
absolute neutrophil count of <500/μl); the use of peri-
toneal dialysis or hemodialysis; and the presence of cen-
tral venous catheters. The sources of secondary BSIs
were identified by cultures of samples obtained from the
primary site of infection that yielded the same pathogen.
Adverse outcomes (organ failure and in-hospital mortal-
ity) occurring during the course of hospitalization were
recorded.
The severity of the underlying disease preceding the
positive blood culture was classified by use of the Charlson
weighted comorbidity índex [12]. The patient's physio-
logical condition on the day of the BSI was assessed by
using the APACHE II score [13], SAPS II [14] and the
SOFA score [15]. At the onset of the BSI, the clinical con-
dition of each patient was classified as systemic inflamma-
tory response syndrome (SIRS), sepsis, severe sepsis, or
septic shock using criteria previously published by the
American College of Chest Physicians/Society of Critical
Care Medicine [16]. SIRS was defined as two or more of
the following: (i) a temperature of >38°C or <36°C, (ii) a
heart rate of >90 beats per minute, (iii) a respiratory rate
of >20 breaths per minute or a partial arterial CO2pressure of <32 mm Hg, or (iv) a white blood cell count
of >12 ×109/liter or <4 ×109/liter or the presence of
more than 10% immature neutrophils.
Severe sepsis was defined as organ dysfunction, hypo-
tension, or systemic manifestations of hypoperfusion.
Septic shock was defined as sepsis associated with
hypotension unresponsive to intravenous fluid chal-
lenge or the need for treatment with a vasopressor
agent. The presence of organ system failure at the time
of the BSI and during the clinical course was assessed
by using the criteria described by Fagon et al. [17].
Nosocomial infection was defined as an infection that
occurred >48 h after hospital admission, an infection
that occurred <48 h after admission to the hospital for
patients who had been hospitalized in the 3 weeks prior
to the admission, or an infection that occurred <48 h
after admission to the hospital for patients who had
been transferred from another hospital or nursing home
[18]. The sources of infection were also defined
according to Centers for Disease Control and Preven-
tion criteria [18]. Time to positivity was defined as the
time between the start of incubation and the time to
sounding of the alert signal on the automated blood
culture instrument. Adequate empirical antifungal
treatment was defined as therapy that was administered
within 24 h after samples for blood culture were
obtained that included any antifungal agent to which
Candida albicans was susceptible [6].Microbiological methods
Blood cultures were processed by the institution's clin-
ical laboratory using the BACTECW9240 blood culture
instrument (Becton Dickinson, Maryland, EUA). Each
blood culture set consisted of an FA aerobic bottle and
an SN anaerobic bottle. All the samples of blood
cultures were collected and submitted in a timely man-
ner to the microbiology laboratory. All cultures were
obtained via peripheral venipuncture and at least two
bottles were obtained for each patient. The bottles were
loaded into the instrument (24 h a day, 7 days a week)
without delay at any time of the day. The time to posi-
tivity of the first bottle in a set to be flagged as positive
was used to determine the time to positivity and was
obtained by using the system's software.
The confirmation of the species was performed by
screening for C. albicans using CHROMagar Candida W-
(CHROMagar Microbiology, Paris, France). Samples of
non-albicans Candida were identified by biochemical pro-
file, the manual method ID 32 CW (BioMérieux, Marcy-l
'Étoile, France) and supplemented by analysis of subcul-
ture microculture. Initial identification of C. albicans by
CHROMagar test - CandidaW was confirmed by the pres-
ence of chlamydoconidia in microculture.
Table 1 Demographic characteristics of 89 patients with
C. albicans BSI
Variables N %
Gender
Male 54 60.7
Female 35 39.3
Age (years)
<60 38 42.7
≥60 51 57.3
ICU 20 22.5
Diagnosis on admission
Gastrointestinal disease 24 27.0
Respiratory disease 19 21.4
Neoplasm 11 12.3
Neurologic disease 6 6.8
Cardiovascular disease 5 5.6
Trauma 4 4.5
Renal failure 4 4.5
AIDS 2 2.2
Other 14 15.7
Site of infection
Catheter 38 42.7
Abdominal 30 33.7
Respiratory 9 10.1
Urinary 8 9.0
Other 4 4.5
Hospital stay prior to BSI (days)
≤2* 1 1.1
3-7 4 4.5
8-14 11 12.3
15-21 10 11.3
>21 63 70.8
Time to positivity
≤24 hs 16 18.0
>24 --≤36 hs 23 25.8
>36–≤48 hs 20 22.5
>48hs 30 33.7
Receiving adequate antifungal therapy
No 69 77.5
Yes 20 22.5
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Continuous variables were compared by using the Stu-
dent t test for normally distributed variables and the
Mann–Whitney U test for nonnormally distributed vari-
ables. Differences in proportions were compared by a
chi-square test or Fisher's exact test, when appropriate.
Mean values ±1 standard deviation were reported. Alpha
was set equal to 0.05, and all tests of significance were
two tailed. When collinearity was identified between two
variables in a correlation matrix, the one with the
greatest clinical relevance associated with mortality was
included in the multivariate analysis. Odds ratios (ORs)
with 95% confidence intervals (CIs) were calculated for
all variables. Variables found to be significant by univari-
ate analysis were then entered into a multivariate model.
All statistical analyses were done by using the Statistical
Package for the Social Sciences software (SPSS, Inc.,
Chicago, IL).
Results
Study population and patient characteristics
A total of 272 patients with episodes of Candida spp
BSIs were identified at Hospital São Paulo during the 7-
year study period. Of these, 101 patients were excluded;
14 patients were on antifungal therapy when blood sam-
ples for culture were obtained, 22 patients because they
had polymicrobial BSIs, and 65 due to incomplete data
in medical records. Of the remaining 171 patients, 89
had Candida albicans BSI and were further analyzed.
The other 82 patients had infection due to non-albicans
species.
The mean age of patients with Candida albicans BSI
was 62.5 ± 16.5 years (range, 18 to 93 years). Fifty-seven
patients (57.3%) were over 60 years of age. The most
frequent diagnoses responsible for hospitalization were
gastrointestinal diseases (27.0%), respiratory diseases
(21.4%), and solid and hematologic malignancies (12.3%).
The most frequent sources of BSIs were central venous
catheters (42.7%) and gastrointestinal (33.7%). Most BSIs
(70.8%) occurred after 21 days of hospitalization (Table 1).
Time to positivity
The mean time to positivity was 41.9 h ± 19.2 hours
(range 6.7 to 95.2 hours) for Candida albicans. In ap-
proximately half of the cases (56.2%) growth of Candida
albicans occurred within 36 hours. We therefore divided
the cases into two groups: patients with an early time to
positivity (TTP of ≤36 h) and patients with a late time to
positivity (TTP of >36 h). Associated risk factors and
outcomes of the two TTP groups are summarized in
Table 2.
Neoplasia was more commonly associated with a BSI
TTP of ≤36 h than with a TTP of >36 (41.0% and 20.0%,
respectively; P = 0.030). Blood transfusion was also morecommonly associated with a BSI TTP of ≤36 h (53.8.0%
vs. 30.0%; P = 0.023). Central venous catheters were
more commonly associated with a BSI TTP of ≤36 h
(56.4% vs. 32.0%; P < 0.04). There was also a statistically
significant difference in the proportion of patients with
gastrointestinal sources of BSIs between the two groups
Table 2 Univariate analysis of factors associated with time to positivity in C. albicans BSIs
Variables Time to positivity ≤36 hs (n=39) Time to positivity >36 hs (n=50) P
N % N %
Demographic characteristics
Age, mean years ±SD 58.4±17.8 65.6±14.8 0.04
Male 25 64.1 29 58.0 0.56
Underlying conditions
Charlson ≥3 23 59.0 26 52.0 0.51
Rapidly fatal disease (MacCabe) 26 66.7 28 56.0 0.31
Diabetes 6 15.4 13 26.0 0.23
Neoplasia 16 41.0 10 20.0 0.03
Neutropenia 1 2.6 2 4.0 0.44
Surgery 24 61.5 26 52.0 0.34
Blood transfusion 21 53.8 15 30.0 0.02
Conditions related to the clinical course
APACHE II score ≥20 at BSI onset 11 28.2 23 46.0 0.09
Adequate antifungal therapy 13 33.3 7 14.0 0.03
Source of infection
Intravascular catheter 22 56.4 16 32.0 0.04
Gastrointestinal 7 17.9 23 46.0 0.01
Respiratory tract 5 12.8 4 8.0 0.45
Urinary tract 3 7.7 5 10.0 0.71
Other 2 5.2 2 4.0 0.83
Outcomes
Organ failure 31 79.5 38 76.0 0.70
Septic shock 18 46.2 20 40.0 0.56
Respiratory failure 26 66.7 36 72.0 0.59
Renal failure 15 38.5 18 36.0 0.81
Hematologic failure 1 2.6 4 8.0 0.26
Hepatic failure 3 7.7 5 10.0 0.71
In-hospital mortality 29 74.4 41 82.0 0.38
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P=0.01, respectively). Patients with early positive cul-
tures were more likely to have received adequate anti-
fungal therapy (33.3% vs. 14.0%; P = 0.03).Clinical course
No statistically significant differences were observed in
organ dysfunction and in-hospital mortality between the
two groups (Table 2). There was a trend for patients
with late positivity to have an APACHE II score≥20 at
BSI onset (46.0% vs. 28.2%; P=0.09) (Table 2).
Univarate analysis revealed that APACHE II score≥20 at
BSI onset, the development of at least one organ system
failure (respiratory, cardiovascular, renal, hematologic, or
hepatic), SOFA at BSI onset, SAPS II at BSI onset, andtime to positivity were associated with death (Table 3).
Age, gender, inadequate antifungal therapy, Charlson
score of ≥3, and neoplasia were not significant predictors
of mortality on univariate analysis.
Using logistic regression analysis, the only independent
predictor of death was time to positivity (1.04; 95% CI,
1.0-1.1), with mortality increasing 4.0% per hour prior to
culture positivity (Table 3). A second model including
inadequate antifungal therapy still showed that time to
positivity was the only independent predictor of death
(1.03; 95% CI 1.0-1.07).Discussion
Recently it has been shown that shorter time to blood cul-
tures positivity in automated systems has been associated
Table 3 Risk factors for hospital mortality in patients with C. albicans BSI
Variables Died (n=70) Recovered (n=19) Univariate analysis Multivariate analysis
N % N % OR CI 95% OR CI 95%
Age >60 years 43 61.4 8 42.0 2.2 0.78-6.13
Male gender 45 64.3 9 47.4 0.5 0.18-1.39
APACHE II score ≥20 at BSI onset 32 45.7 2 10.5 7.2 1.54-33.35 2.1 0.3-12.8
Organ failure (at least one) 59 84.2 10 52.5 4.8 1.60-14.60 2.9 0.6-13.2
Respiratory failure 54 77.1 8 42.1 4.6 1.60-13.50
Cardiovascular failure 35 50.0 3 15.8 5.3 1.43-19.95
Renal failure 29 41.4 4 21.0 2.7 0.80-8.82
Hematologic failure 5 7.1 - - 1.3 1.15-1.45
Hepatic failure 8 11.4 - - 1.3 1.16-1.47
Inadequate antifungal therapy 55 78.6 14 73.7 1.31 0.41-4.22
Charlson score ≥3 40 57.1 9 47.3 1.5 0.54-4.10
Neoplasia 20 28.5 6 31.5 0.9 0.29-2.60
SOFA at BSI onset, mean (±SD) 6.7 (4.3) 3.6 (2.3) 1.28 1.07-1.52 1.05 0.8-1.3
SAPS II at BSI onset, mean (±SD) 48.4 (15.4) 35.2 (14.3) 1.06 1.02-1.11 1.04 0.9-1.1
Time to positivity (in hours), mean (±SD) 43.9 (19.8) 34.6 (15.4) 1.03 1.0-1.06 1.04 1.0-1.1
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shorter times are associated with higher mortality) [9-11].
This has been shown for S. aureus [9], Streptococcus
pneumoniae [11] and Escherichia coli BSI [10]. These
findings prompted us to study the time to positivity of
candidemia (C. albicans), since the studies analyzing time
of positive Candida spp culture are rare and almost all
were performed in vitro [19-21].
In our study, only the time to blood culture positivity
was predictive of mortality for Candida albicans. The
severity of illness (APACHE II, SAPS II and SOFA) was
not significantly different between the two groups.
We identified in the medical literature only three clin-
ical studies that analyzed the time to positivity for
candidemia, but these had different goals: comparing
the differential time to positivity between specimens
obtained peripherally and via a central venous catheter
[22]; quantifying the time between the collection of
blood culture and its positivity [8]; and evaluating the
time to positivity for detecting Candida species resist-
ant to fluconazole [23].
Regarding Candida albicans BSI, our study showed
the longer the time to positivity, the higher the mortal-
ity. We found only one report with a similar finding and
this was for Staphylococcus aureus bacteremia [24]. In
this retrospective study they observed that a shorter time
to positivity was associated with methicillin susceptibility
and an endovascular source; multivariate analysis showed
higher mortality both with time to positivity ≤ 12 or >48
hours [24].Physicians often wait for the blood cultures to grow
Candida prior to beginning antifungal therapy. However,
even if the patient has a stable clinical condition and not
receiving empirical antifungal treatment, this may be as-
sociated with a poor outcome.
Until the early 2000s, the vast majority of candidemia
cases were diagnosed in intensive care units [3,25]. Recent
studies have shown a decrease in the proportion of Can-
dida BSIs occurring in ICUs, especially in Latin America
countries, with a fall between the years 2008 and 2009
from 64.9% to 42.6% [26].
We observed that only 22.5% of patients with candidemia
(C. albicans) received adequate antifungal therapy in the
first 24 hours after the suspected infection or collection of
blood cultures. Although the reason for not instituting
empiric treatment was not evaluated, we believe it has oc-
curred at least in part, due to the delay in blood culture
positivity. Other studies have also found that candidemia
has one of the highest rates of inadequate empirical treat-
ment in the first 24 hours after suspected infection [6,7].
A multicenter study reported that the mean time for
initiating empiric antifungal therapy was 3.8 days [3].
These data emphasize the need to consider early initi-
ation of empiric therapy given that blood cultures are
slow to turn positive for Candida species.
Comparing the mean time to positivity for Candida
albicans with other studies, we found that the automated
BacT/ALERTW time growth is faster [8,27]. Lai and col-
leagues (2012) reported similar time using the BACTECW
system [23]. It should be noted that in our study we did
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other study also used specific culture medium for fungi
(BACTECTM Myco/F Lytic) whose time to positivity is
known to be shorter, especially in the identification of
non-albicans Candida species. They showed differences
between the mean time to positivity for Candida albicans
between the specific culture medium for fungi versus a
non-specific medium for fungi (aerobic culture), 34 ± 25 h
vs. 42 ± 19 h, respectively [23].
Our study is limited by the retrospective nature of our
analysis. In addition, because of the relatively small sam-
ple size of our study (n=89), a type II error could have
occurred, which would limit the ability to detect a statis-
tically significant difference in the other variables con-
sidered as predictors of mortality.
Conclusions
The present study showed that the time to positivity for
Candida albicans BSI is associated with a significantly
greater risk for mortality. These data suggest that physi-
cians should consider empiric antifungal therapy in
patients with risk factors for candidemia rather than
waiting for the growth of Candida albicans in culture.
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